SCHEMBL9904674

SCHEMBL9904674

Fc1cccc(F)c1-c1ccc2[nH]cc(Br)c2c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 8/20 0.47
PIM3 Q86V86 7/20 0.47
PIM2 Q9P1W9 6/20 0.47
CCNT1 O60563 1/20 0.40
CDK9 P50750 1/20 0.40
HASPIN Q8TF76 1/20 0.40
TYK2 P29597 1/20 0.39
ICMT O60725 2/20 0.38
TRPA1 O75762 1/20 0.37
NR4A2 P43354 1/20 0.37
ALOX5AP P20292 1/20 0.36
FEN1 P39748 1/20 0.36
HTR1A P08908 1/20 0.36
HTR7 P34969 1/20 0.36
TTR P02766 1/20 0.35
AHR P35869 1/20 0.34
GPR84 Q9NQS5 3/20 0.34
FFAR1 O14842 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9904260 0.80 PIM1 (0.47) PIM1PIM3PIM2HASPINTYK2
SCHEMBL14631802 0.74 GPR84 (0.58) HTR1AGPR84
SCHEMBL9904805 0.73 GRIA1 (0.46) PIM1PIM3PIM2HASPINTYK2
SCHEMBL9904218 0.72 PIM1 (0.46) PIM1PIM3PIM2TRPA1ALOX5AP
SCHEMBL29364370 0.70 GPR84 (0.55) PIM1CCNT1CDK9HASPINHTR1A
SCHEMBL28207416 0.70 GPR84 (0.62) PIM1CCNT1CDK9HASPINNR4A2
SCHEMBL7020717 0.68 TRPA1 (0.50) TRPA1ALOX5APFEN1
SCHEMBL23658612 0.67 GPR84 (0.58) GPR84
SCHEMBL14149493 0.67 HTR1D (0.51) PIM1CCNT1CDK9HASPINNR4A2
SCHEMBL5197534 0.67 HTR2C (0.53) HTR1AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US disclosed
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US disclosed
EP-2796456-A1 Bicyclic compounds as Pim inhibitors Amgen Inc. (US) 2014-10-29 EP disclosed
EP-2796456-A1 Bicyclic compounds as Pim inhibitors Amgen Inc. (US) 2014-10-29 EP disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US disclosed
EP-2649065-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2013-10-16 EP disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 WO disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS PIM1, PIM2, PIM3 PIM1 1/4885PIM3 3/4885PIM2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.